Kairos Pharma reports interim Phase 1 safety data for ENV-105 with Tagrisso in EGFR-mutated lung cancer
KAPA•Interim Phase 1 safety data
Kairos Pharma released interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in advanced EGFR-mutated NSCLC.
No Grade 3 or higher adverse events were reported in 13 treated patients; results support continued dosing toward an early efficacy readout.
Program focus and market backdrop
The program targets acquired resistance to osimertinib in an EGFR-NSCLC market estimated at about $10 billion. Tagrisso generates about $6 billion in annual sales.
